financetom
Business
financetom
/
Business
/
Battery maker Microvast Q2 revenue misses expectations
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Battery maker Microvast Q2 revenue misses expectations
Aug 11, 2025 2:30 PM

Overview

* Microvast Holdings ( MVST ) Q2 revenue rises 9.2% to $91.3 mln, misses analyst expectations, per LSEG data

* Adjusted EBITDA turns positive at $25.9 mln, compared to negative $78.4 mln last year

* Company's gross margin increased to 34.7% from 32.5% in Q2 2024

Outlook

* Microvast ( MVST ) targets 2025 revenue between $450 mln and $475 mln

* Company updates 2025 gross margin target to 32%

* Microvast ( MVST ) plans Huzhou expansion completion by year-end

Result Drivers

* INCREASED DEMAND - Co attributes revenue growth to increasing demand for advanced battery solutions

* OPERATIONAL EFFICIENCY - Improved gross margin and positive adjusted EBITDA reflect focus on operational efficiency

* COST MANAGEMENT - Significant reduction in operating expenses contributed to financial performance

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $91.30 $106.80

Revenue mln mln (3

Analysts

)

Q2 Beat $0.05 $0.01 (2

Adjusted Analysts

EPS )

Q2 Beat $16.30 $3.58

Adjusted mln mln (2

Net Analysts

Income )

Q2 Net -$106.10

Income mln

Q2 Beat $25.90 $17.10

Adjusted mln mln (3

EBITDA Analysts

)

Q2 $16.50

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the electrical components & equipment peer group is "buy"

* Wall Street's median 12-month price target for Microvast Holdings Inc ( MVST ) is $4.00, about 27.7% above its August 8 closing price of $2.89

* The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 93 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Torpedo Bats Take Over MLB, Sportsbooks: Public Company Sees Soaring Demand For Home Run Hitting Baseball Bat
Torpedo Bats Take Over MLB, Sportsbooks: Public Company Sees Soaring Demand For Home Run Hitting Baseball Bat
Apr 3, 2025
Anyone following Major League Baseball in the 2025 season has heard about torpedo bats, a new trend of bats that have seen impressive results for those using them. A deep dive into legal bats shows soaring demand and a public company that gives investors exposure to the latest hitting trend. What Happened: The New York Yankees lost the 2024 World...
Trump administration sued over Chinese import tariffs
Trump administration sued over Chinese import tariffs
Apr 3, 2025
(Reuters) - New Civil Liberties Alliance, a conservative legal group, on Thursday filed what it said was the first lawsuit seeking to block Donald Trump's tariffs on Chinese imports, saying the U.S. president overstepped his authority. The lawsuit, filed in federal court in Florida, alleges that Trump lacked the legal authority to impose the sweeping April 2 tariffs as well...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
GSK resolves patent lawsuit against Pfizer over RSV vaccines
GSK resolves patent lawsuit against Pfizer over RSV vaccines
Apr 3, 2025
(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer ( PFE ) have agreed to end a lawsuit that alleged Pfizer's ( PFE ) respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent rights in its competing RSV shot Arexvy, according to a Thursday filing in Delaware federal court. GSK and Pfizer ( PFE ) said in the filing that they...
Copyright 2023-2026 - www.financetom.com All Rights Reserved